Univariate analysis revealed that a disease duration greater than 1 year (OR, 0.26, 95% CI 0.07–0.85), IBD-type (UC; OR, 0.15, 95% CI 0.03–0.66), and concomitant corticosteroid therapy (OR, 0.25, 95% CI 0.07–0.81) were significant factors for clinical remission after 52 weeks of anti-TNF treatment (Table 3). The gene discussed is TNF; the disease is inflammatory bowel disease.